Artiva Biotherapeutics (ARTV) investor relations material

Differentiation and approach in cell therapy for autoimmune disease

• Focus on deep B cell depletion as a mechanism for treating autoimmune diseases, leveraging experience from oncology trials.

• AlloNK offers an off-the-shelf, non-genetically modified NK cell therapy with biologics-like tolerability, administered in community settings.

• Therapy uses monoclonal antibodies for targeting, avoiding the complexity and long-term monitoring of engineered cell products.

• Manufacturing scalability allows for low cost of goods, with projected COGS of $3,000–$12,000 per dose.

Clinical trial progress and safety profile

• Over 100 patients treated, including oncology and autoimmune indications; 32 autoimmune patients treated as of the latest update.

• Clean safety profile: no CRS, ICANS, or GVHD; only one hospitalization for infection among 32 patients.

• Low-dose cyclophosphamide and fludarabine used, with tolerability similar to biologics like rituximab.

• No adverse events specifically attributable to NK cells observed; safety profile supports community-based administration.

Translational and efficacy data

• High-sensitivity assays show complete peripheral B cell depletion in all treated patients at some point post-treatment.

• B cell reconstitution begins around six months, with >95% of returning cells being naive or transitional, mirroring AutoCAR T results.

• Deep B cell depletion in tissue inferred from oncology experience and peripheral data.